25 results about "Fecal microbiota" patented technology

Disclosed herein are methods for administering a dose of a microbiota recovery therapy composition by colonoscopy. The methods disclosed herein are useful for the treatment of diseases and / or conditions of the digestive tract, such as Clostridium difficile infection (GDI), including recurrent GDI, and other gastrointestinal disorders. The method can result in improved quality of life. These methods are capable of altering the gut microbiota composition and / or the gut metabolome composition. The microbiota recovery therapy composition comprises a fecal microbiota suspension comprising: a fecal microorganism derived from a human fecal sample, and a solution of polyethylene glycol and brine.

Provided are a method for predicting a treatment response to cancer immunotherapy, the method comprising a step of evaluating, from feces isolated from a patient, the enrichment of a strain of the order TANB77 according to GTDB phylogenetic classification or taxa belonging to the order TANB77, and a step of predicting a treatment response of the patient to cancer immunotherapy on the basis of the enrichment of the order TANB77 or the taxa; a probiotics composition for improving a treatment response; a fecal microbiota transplantation composition; and a method for screening for candidate prebiotics by using same.

The application discloses a kind of based on 5 kinds of bacteria combination's flora transplantation donor screening technique and its application in tumor immunotherapy, the intestinal flora includes Eubacterium rectale, Adlercreutzia equolifaciens, Megamonas hypermegale, Lachnospiraceae bacterium (5_1_63FAA), Gordonibacter pamelaeae One or more of them.The application is screened and found that the abundance of the intestinal flora in the obese cancer patients with immune checkpoint inhibitor treatment response is significantly improved, and can be used to predict the immune checkpoint inhibitor treatment effect of cancer patients.The flora transplantation preparation containing the relative abundance of the intestinal flora is greater than or equal to 8.51%, and after combination treatment with immune checkpoint inhibitor, the tumor immunotherapy effect can be significantly improved.

This invention relates to fecal microbiota transplantation (FMT) formulations for treating lung cancer, their screening methods, and applications. The invention establishes a microbiome-based quantitative screening system based on the characteristics of the lung cancer immune microenvironment, achieving a precise match between donor screening criteria and tumor-specific immune regulation needs. This overcomes the limitations of traditional FMT formulation preparations that rely on universal health standards, providing reliable support for clinical applications. Furthermore, the invention develops a combined application strategy of FMT formulations and immune checkpoint inhibitors, which can significantly improve disease control rates and prolong progression-free survival in lung cancer patients, providing an innovative solution to overcome drug resistance challenges in lung cancer immunotherapy.

This invention discloses a dietary factor and its combination that targets gut microbiota to improve exercise performance, belonging to the fields of microbial technology and pharmaceutical technology. Experimental verification shows that the dietary factor combination can increase the abundance of *Eubacterium rectale*, *Faecalibacterium prausnitzii*, and *Veillonella* species; a combination of galactooligosaccharides, burdock seed, matsutake polysaccharide, and galactooligosaccharides; a combination of burdock seed and matsutake polysaccharide; and a combination of burdock seed and galactooligosaccharides can increase the concentration of fatty acid amides; curcumin and the combination of curcumin, burdock seed, and galactooligosaccharides show the best effect in promoting the content of fecal microbiota after acetic acid fermentation; and a mixed combination of *Bifidobacterium adolescentis* CCFM1066, *Bifidobacterium longum* CCFM1306, curcumin, inulin, burdock seed, matsutake polysaccharide, and galactooligosaccharides shows the most significant effect in increasing the time spent swimming at exhaustion under load in exercised mice.

This invention discloses a method for characterizing and isolating gut microbiota capable of specifically uptake or metabolizing natural products, comprising: in vitro co-culture, click chemistry reaction, and flow cytometry sorting. Based on click chemistry technology, this invention co-cultures alkyne-modified natural products with fecal microbiota. Through a copper-catalyzed azido-alkynyl cycloaddition reaction, azidolated fluorescent dyes are labeled onto all bacteria capable of uptake and utilizing natural products or their metabolites. These bacteria are then isolated using flow cytometry sorting. Compared to methods for studying metabolism and utilization using single-species culture, this invention is lower in cost and shorter in time, providing a new approach for extensive and in-depth research on the interaction between gut microbiota and natural products.

The present application relates to a quality control product for quality evaluation of a preparation for intestinal flora transplantation, a preparation method and application thereof. The quality control product comprises a complex microbial component, an internal standard component, a simulated matrix and a stabilizer. The present application adopts a "multi-donor mixing" method, and compared with a scheme based on cultured strains, the quality control product prepared by the present application is highly consistent with a real FMT preparation in terms of species composition, relative proportion and bacterial activity state, and the quality control result has a strong clinical relevance. By constructing a "core bacterial spectrum", the complex flora quality control becomes simple, focused and cost controllable. In addition, the use of bifidobacterium as an internal standard has better compatibility with the sample matrix, more accurate monitoring and completely eliminates the risk of exogenous contamination.

Disclosures herein relate to methods of producing oral powdered compositions for fecal microbiota transplant including desired microbes and related methods of treatment. Procedures for producing the powdered composition may include filtering a fecal sample, separating particulate matter of the filtrate, repeatedly resuspending the sediment and separating particulate matter, diluting the supernatant and repeatedly separating particulate matter out of the supernatant, resuspending the sediment in a cryoprotectant to obtain a mixture, and freeze-drying the mixture to obtain a freeze-dried, powdered composition, wherein the powdered composition may be substantially tasteless, odorless, and colorless. The FMT composition has an odor as evaluated with a confidence of 95% to be odorless for more than 50% of the population using a triangular test and a flavor as evaluated with a confidence of 80% to be flavorless for more than 50% of the population using the triangular test.

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition.The invention also provides processes for its preparation as well as it use in therapy.The live-cell based composition of the invention is stable at mild conditions.

The present disclosure provides freeze-dried compositions that include an extract of human feces and a flavoring agent, where the compositions, upon reconstitution with a liquid, have no objectionable odor and has no objectionable taste. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease. In some embodiments, the subject can be an individual with reduced ability to swallow, such as pill dysphagia, or an individual refractory to administration of a liquid having an objectionable odor or objectionable taste.

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of live microorganisms and one or more pharmaceutically acceptable water-absorbing excipients, wherein the water content of the composition is between 0.5% and 30% by weight of the total composition, as determined according to the European Pharmacopoeia 9.4 section 2.5.12. The present invention also provides a process for its preparation and its use in therapy. The live cell-based composition of the present invention is stable under mild conditions.

The present application relates to a kind of preparation method of fecal bacteria for intestinal flora transplantation.The present application includes the following steps: (1) preparation of intestinal flora reticular carrier; (2) preparation of intestinal flora suspension; (3) preparation of bionic intestine; (4) in vitro continuous culture of intestinal flora; (5) collection after intestinal flora culture.The present application provides a preparation method of fecal bacteria for intestinal flora transplantation, which realizes in vitro culture of intestinal flora by simulating the living environment of intestinal flora in human intestine, ensures the stability of flora quality and yield, eliminates the time limit of intestinal flora transplantation treatment, and greatly improves the timeliness of clinical application.The intestinal flora prepared by the present application has large yield and high activity.Furthermore, the intestinal flora of the present application has obvious improvement in relieving weight loss of inflammatory bowel disease patients, relieving food utilization coefficient decline of inflammatory bowel disease patients, relieving red blood cell quantity decline of inflammatory bowel disease patients, reducing white blood cell quantity of inflammatory bowel disease patients and improving intestinal beneficial bacteria content.

Aspects of the disclosure encompass compositions and therapeutic methods for treating subjects having gastrointestinal disorders. The compositions provided herein can be formulated as live biotherapeutic products (LBP), fecal microbiota transplant (FMT) products and FMT enrichment compositions, probiotics and food products, and comprise one or more of the bacterial species Faecalibacterium prausnitzii, Bifidobacterium adolescentis, Bifidobacterium longum, Eubacterium rectale or combinations thereof. In certain aspects, an individual is determined to be a suitable recipient for these therapies based on classification of the taxa profile of their microbiome.

The invention provides an excrement middle and rear section sampler for intestinal flora transplantation, and relates to the technical field of intestinal flora transplantation, the excrement middle and rear section sampler comprises a funnel section, a first pipe section, a second pipe section and a third pipe section which are connected in sequence, an interlayer groove is formed in one end, close to the first pipe section, of the funnel section, and stacked containing sleeves are arranged in the interlayer groove; the upper end of the containing sleeve is in sealing connection with the funnel section, the lower end of the containing sleeve penetrates through the annular groove in the inner circumference of the interlayer groove and is a closed end, and the second pipe section is provided with an opening; the problem that the middle and rear sections of excrement cannot be accurately, selectively and conveniently sampled during excrement sample sampling in the prior art is solved.

The invention belongs to the technical field of biology, and discloses application, a screening method and a medicine of Brawler's bacteria, and application of the Brawler's bacteria to preparation of anti-inflammatory drugs. Firstly, it is determined that intestinal microorganisms play an important role in resisting salmonella infection through a fecal microorganism transplantation test; secondly, screening is carried out on excrement extracts of chicken infected with salmonella, it is found that the abundance of the Brawler is extremely high, and it is further found through in-vitro tests and in-vivo tests that the Brawler can inhibit the systemic inflammatory response, caused by infection of salmonella enteritidis, of the chicken.

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of live microorganisms and one or more pharmaceutically acceptable water-absorbing excipients, wherein the water content of the composition is between 0.5% and 30% by weight of the total composition, as determined according to the European Pharmacopoeia 9.4 section 2.5.12. The present invention also provides a process for its preparation and its use in therapy. The live cell-based composition of the present invention is stable under mild conditions.

The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.

The invention relates to the technical field of coprophilous fungus transplantation, in particular to a coprophilous fungus capsule for reducing uric acid and a preparation method and application thereof. The coprophilous fungi capsule comprises a wall material and a core material, the wall material is an enteric capsule shell, and the core material comprises whole coprophilous fungi and poria cocos enzymatic hydrolysate; the concentration of effective viable bacteria in the whole coprophilous fungus composite capsule is at least 2.5 * 10 < 12 > CFU / g. According to the preparation method, coprophilous fungus transplantation and microbial fermentation are combined, whole coprophilous fungi are added into poria cocos enzymatic hydrolysate to prepare the coprophilous fungus capsules, the poria cocos enzymatic hydrolysate provides carbohydrate prebiotics, meanwhile, the content of poria cocos triterpenes in the poria cocos enzymatic hydrolysate is increased through coprophilous fungus fermentation, the diuretic effect of the coprophilous fungus capsules is enhanced, and the uric acid reducing effect of the coprophilous fungus capsules is assisted. The coprophilous fungus capsule reduces uric acid from multiple aspects of direct uric acid reduction, harmful bacterium growth inhibition, diuresis and inflammation resistance, and provides a new thought for uric acid reduction.

The invention relates to the field of treatment of obesity by flora transplantation, in particular to a marker combination related to an obesity donor, a product and application of the marker combination. The biomarker composition is prepared from the following components: Bifidobacterium adolescentis, Alistipes shaii, Odorobacter splanchnicus, and Bacteroides plebeius, and is characterized in that the biomarker composition is prepared from the following components: Bifidobacterium adolescentis, Alistipes shaii, Odorobacter splanchnicus, and Bacteroides plebeius. The invention provides a reagent for detecting the marker combination, which can be used for preparing a product for screening / evaluating flora transplantation treatment of obesity donors, a computer readable storage medium containing a donor curative effect judgment instruction, and a donor curative effect evaluation system containing a detection device and a comparison device. The invention discloses the association between the flora and the obesity donor for the first time, is non-invasive and high in accuracy, fills the blank of lack of specific markers for treating the obesity donor by flora transplantation, and provides a basis for obesity diagnosis and treatment and individualized treatment.

The invention belongs to the technical field of molds, and discloses an intestinal flora transplantation capsule mold which comprises two placing plates, clamping devices are arranged in the placing plates, and a folding device is arranged between the two placing plates. According to the capsule clamping device, through linkage of the mold groove, the swing rod, the first sliding rod and the clamping plate, capsules can be stably clamped, displacement of the capsules in the mold is avoided, and a precise positioning foundation is provided for subsequent machining (such as filling and packaging); according to the folding device, the two placing plates can be stably and accurately folded by utilizing the thread transmission characteristic of a two-way screw rod and a thread block in cooperation with mechanical linkage of a connecting rod, it is ensured that the upper structure and the lower structure of a capsule mold are aligned in the forming process, the consistency and precision of mold production are improved, errors caused by manual operation are reduced, and the production efficiency is improved. The production quality and efficiency of the intestinal flora transplanted capsules are effectively improved, and practical application and operation are facilitated.

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition.The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.

The invention belongs to the field of medicines, and particularly relates to application of Z-ligustilide in a medicine for treating migraine. Z-ligustilide is combined with fecal fungus transplantation (FMT), by adjusting host intestinal flora and metabolites, the community structure and metabolic function of the intestinal flora can be recovered, the level of neurotransmitters such as serotonin can be adjusted, the migraine symptom can be relieved through the multi-target effect, the clinical symptom of migraine can be improved through multiple ways through the Z-ligustilide combined fecal fungus transplantation technology (FMT), and the migraine treatment effect is improved. The treatment effectiveness is improved.

1. The name of the design product: Fecal microbiota transplantation freeze-dried powder capsule automatic assembly machine. 2. The use of the design product: The design product is used for assembling and producing freeze-dried powder capsules. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The present application belongs to the technical field of pharmaceutical preparation. Provided is a method for drying a multi-layer fecal microbiota dropping pill. The drying method of the present application comprises: subjecting a multi-layer fecal microbiota dropping pill to centrifugal deoiling with a deoiling agent, followed by a separation treatment to obtain a deoiled dropping pill, wherein the deoiling agent is a mixture of fumed silica, soybean fiber and oat cellulose; subjecting the deoiled dropping pill to blast drying to obtain a pre-dried dropping pill; and subjecting the pre-dried dropping pill to negative-pressure drying to obtain a Huanglong dropping pill. According to the drying method provided by the present application, centrifugal deoiling, blast drying and negative-pressure drying are sequentially performed to further reduce the water activity of the Huanglong dropping pill. Data from the examples demonstrate that the obtained Huanglong dropping pill has a water activity (aw) of 0.08-0.14, exhibiting an excellent tolerance, particularly an in vitro simulated gastrointestinal tolerance, and an excellent stability.

Disclosed herein are methods for administering a dose of a microbiota restoration therapy composition by colonoscopy. The methods disclosed herein are useful for treating diseases and / or conditions of the digestive tract, such as Clostridioides difficile infection (GDI), including recurrent GDI, and other gastrointestinal disorders. The method may result in improved quality of life. The methods may alter gut microbiota composition and / or gut metabolome composition. The microbiota restoration therapy composition comprises a fecal microbiota suspension comprising: fecal microbes derived from a human fecal sample, and a solution of polyethylene glycol and saline.